Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.
Alexander I Spira, David Berz, Robert M Jotte...
https://pubmed.ncbi.nlm.nih.gov/41385873/Actively Recruiting
Led by Genprex, Inc. · Updated on 2026-09-16
158
Participants Needed
10
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of quaratusugene ozeplasmid Reqorsa combined with osimertinib in patients with advanced metastatic or recurrent non-small cell lung cancer NSCLC that has specific EGFR mutations and has worsened despite osimertinib treatment. This study includes a Phase 1 dose escalation portion and two Phase 2 parts to assess treatment safety and tumor response. It is an open-label, multi-center, randomized trial comparing the investigational combination therapy against platinum-based chemotherapy. Participants in Phase 1 and Phase 2a receive quaratusugene ozeplasmid intravenously every 21 days plus daily oral osimertinib at a fixed 80 mg dose in 21-day cycles until disease progression or unacceptable side effects. In Phase 2b, patients are randomly assigned to either the combination therapy or platinum-based chemotherapy, continuing treatment until progression or intolerable toxicity. Some patients may also receive local therapies like radiation before enrollment. Throughout the study, participants undergo regular safety assessments including monitoring for adverse events and dose-limiting toxicities. Researchers evaluate outcomes such as the recommended dose, overall response rate, progression-free survival, duration of response, pharmacokinetics, and overall survival at specified intervals. The trial involves ongoing clinical evaluations, laboratory tests, tumor biopsies, and imaging to track disease status and treatment effects over several months to years.
CONDITIONS
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
S
Sr Director, Clinical Operations
C
Chief Medical Officer
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Genprex, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational: Q‑ozeplasmid + osimertinib | Control: osimertinib | External Context: platinum‑based chemotherapy |
|---|---|---|---|
| What it is | An experimental non‑viral immunogene therapy delivering the TUSC2 gene combined with osimertinib | Single‑agent osimertinib continuation after progression (control arm) | Systemic platinum‑based chemotherapy is commonly used after progression on osimertinib in EGFR‑mutated NSCLC |
| Role in trial | Investigational experimental treatment arm | Active comparator arm continuing osimertinib | Established post‑progression treatment outside this trial |
| Primary use | To test whether adding TUSC2 immunogene therapy to osimertinib delays further progression | Continuation of osimertinib alone after progression as control comparator | Standard systemic chemotherapy for disease control after osimertinib progression |
| How it is given or performed | TUSC2 gene delivered via non‑viral vector alongside daily oral osimertinib | Daily oral osimertinib | Intravenous platinum‑based chemotherapy, typically cisplatin or carboplatin with pemetrexed |
| Evidence status | Efficacy under investigation in this trial; no published results yet | Continuation of osimertinib efficacy limited by progression, not expected to control disease long term | Chemotherapy has variable and often limited benefit after EGFR‑TKI progression |
| Important risks | Risks not yet established; safety under investigation | Known TKI risks such as skin rash, diarrhoea, and rare interstitial lung disease (not detailed in trial registry) | Chemotherapy risks include marrow suppression, nausea, fatigue, and renal or neurologic toxicity |
| Important limitations | Experimental therapy; unknown efficacy and safety profile | Disease has already progressed on osimertinib, making further benefit unlikely | Systemic chemotherapy offers modest benefit and increased toxicity after prior targeted therapy |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for assessments and tumor biopsy
Duration - Up to approximately 11 months
Participants receive either quaratusugene ozeplasmid combined with osimertinib or platinum-based chemotherapy until disease progression or unacceptable side effects.
Treatment cycles every 21 days with regular clinical visits
Duration - Up to approximately 21 months
Participants are monitored for safety and disease status after treatment ends through clinical evaluations and imaging.
Periodic visits for assessments and monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alexander I Spira, David Berz, Robert M Jotte...
https://pubmed.ncbi.nlm.nih.gov/41385873/Genprex, Inc.
Lead Sponsor